Panel A shows progression free survival of the entire cohort. Patients who received FM100 conditioning had significantly better progression-free survival comparedwith those who received FM140 conditioning (p=0.014).
Panel B shows progression free survival of patients with favorable or intermediate SWOG cytogenetic risk. Patients received FM100 conditioning had significantlybetter progression-free survival compared with those who received FM140 conditioning (p=0.05).
Panel C shows progression-free survival of patients with SWOG high-risk cytogenetics. A higher progression-free survival was seen in patients who received FM140conditioning as compared to FM100 group (p=0.013).
Panel D shows progression-free survival of patients with favorable or intermediate-I or intermediate-II risk group according to ELN classification. FM 100 was associatedwith a better progression-free survival as compared to FM140 conditioning (p=0.019).
Panel E shows progression-free survival of patients with adverse risk according to ELN classification. Patients who received FM140 conditioning had a significantly better progression-free survival compared with FM140 conditioning (p=0.041).
